The JAG1 Knockout A2780 Polyclonal Cells represent a heterogeneous polyclonal cell population derived from the A2780 ovarian carcinoma cell line, featuring CRISPR/Cas9-mediated disruption of the JAG1 gene. This gene-edited product provides a pooled loss-of-function model suitable for studying the collective effects of JAG1 ablation without the lineage-specific bias of isolated clones. The polyclonal format allows robust population-level analysis of Notch pathway inhibition, offering a versatile resource for researchers investigating JAG1-dependent mechanisms in ovarian cancer biology.
The A2780 cell line is a well-established human ovarian carcinoma model originally derived from an untreated patient and characterized by wild-type p53. These epithelial cells are extensively used to study ovarian cancer hallmarks including proliferation, metastasis, and therapeutic response, particularly to platinum- and taxane-based agents such as cisplatin and paclitaxel. The wild-type p53 status makes A2780 especially relevant for evaluating DNA damage responses and chemosensitivity within oncogenic contexts.
JAG1 encodes Jagged1, a canonical ligand for Notch receptors (NOTCH1?C4). Ligand binding triggers sequential proteolytic processing by ADAM17 and the gamma-secretase complex, releasing the Notch intracellular domain (NICD). NICD translocates to the nucleus, where it interacts with the CSL-MAML complex to activate transcription of downstream targets such as HES1, HEY1, MYC, and CCND1. Upstream regulators including TNF-alpha, TGF-beta, and hypoxia/HIF-1?? modulate JAG1 expression, integrating inflammatory and hypoxic signals. This signaling cascade governs cell fate determination, angiogenesis, and epithelial-mesenchymal transition (EMT), and in cancer, Jagged1-driven Notch activation promotes angiogenic switching and metastasis.
In this background, JAG1 disruption allows investigation of Jagged1-dependent oncogenic processes, including Notch-driven angiogenesis and epithelial-mesenchymal transition, which are central to metastasis and chemoresistance. The polyclonal knockout population mimics tumor heterogeneity and provides an ideal system to evaluate average pathway dependencies and phenotypic variability. This model is especially suited for examining Notch signaling interplay with wild-type p53 function and assessing combined therapeutic interventions.
Researchers can utilize JAG1 Knockout A2780 Polyclonal Cells in a range of functional assays to dissect Notch pathway biology in ovarian cancer. Representative applications include western blotting for NICD and HES1, RT-qPCR analysis of Notch target gene expression, transwell migration and invasion assays, MTS proliferation assays, flow cytometric assessment of apoptosis, and immunofluorescence detection of Notch protein localization. Drug sensitivity profiling with cisplatin or paclitaxel can reveal the role of JAG1 in chemoresistance. Additionally, these cells serve as a platform for studying angiogenic signaling and EMT regulation. For further information or to inquire about customized solutions, please contact Ascent Research.
